Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
vor 484 Tagen
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
vor 739 Tagen
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
vor 766 Tagen
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
vor 838 Tagen
TSX Ends Modestly Lower
https://money.tmx.com/canadian-markets
https://www.rttnews.com/3499633/bay-street-likely-to-open-slightly-higher.aspx?type=cn
RTTNews
|
vor 1 Tagen
Dollar Turns In Mixed Performance Against Major Counterparts
The U.S. dollar turned in a mixed performance against its major counterparts with traders assessing the Federal Reserve's likely moves with regard to interest rates next year.
RTTNews
|
vor 1 Tagen
U.S. Stocks Close Notably Lower; Nasdaq Sheds 1.5 Percent
U.S. stocks tumbled on Friday and the major averages all closed notably lower with the tech-laden Nasdaq suffering a more pronounced loss as yields on 10-Year Treasury Note rose to near 8-month high.
RTTNews
|
vor 1 Tagen
U.S. Stocks Down Firmly In Negative Territory; Nasdaq Tumbled 1.7 Percent
U.S. stocks are down firmly in negative territory Friday afternoon with rising Treasury yields contributing to the weakness. The major averages are all down in the red with the Nasdaq suffering a more pronounced loss.
RTTNews
|
vor 1 Tagen
